Resources
Technical data sheets, regulatory guides, and market intelligence for cannabis operators, hemp processors, and pharmaceutical manufacturers navigating the post-Schedule III landscape.
Schedule III Rescheduling: The Complete Picture
On April 28, 2026, the U.S. Department of Justice issued the final rule placing FDA-approved drug products containing marijuana and qualifying marijuana activity conducted under a state medical-marijuana license in Schedule III of the Controlled Substances Act. The rule created a more defined federal controlled-substance framework, while product approvals and site requirements remain project specific.
Applicable registration, recordkeeping, reporting, security, labeling, documentation, and tax considerations depend on an operator's specific product, activity, and jurisdiction. Qualifying operators should evaluate their requirements with experienced legal, regulatory, tax, and quality advisors.
For pharmaceutical manufacturers, the rule may inform planning for cannabinoid API projects. Any product-development, manufacturing, or supply strategy remains subject to applicable FDA, DEA, state, quality-system, and commercial requirements.
Equipment-selection guide
Evaluating an Alternative to Separate Wiped-Film or Short-Path Equipment?
Compare the refining job, equipment chain, handoffs, service requirements, utilities and cost per saleable gram. See where the integrated MPS platform fits a crude-to-distillate workflow.
Product Data Sheets
MPS 30 Multi-Processing System
MPS details for THCa isolation, High Terpene Extract separation and distillate refining — vessel configurations, materials, utilities and build-specific documentation.
Request Data Sheet or QuoteExplore the MPS Platform
PROCHILL™ LC-5.000.170 — In Stock
One process chiller: 5 kW cooling at −80°C and 11 kW at −60°C. Review its operating range, flow, fluid-pressure control and remote communications. Subject to prior sale.
Request Data Sheet or QuoteExplore PROCHILL Specifications
ProX Extraction System
Technical specifications for the ProX pharmaceutical-grade hydrocarbon extraction system including ASME BPE and C1D1 configurations.
Request Data Sheet or QuoteExplore the ProX Platform
inTEST Chilling Systems
Thermal management specifications for inTEST industrial chillers, including temperature range, compatibility, and pharmaceutical-grade construction details.
Request Data Sheet or QuoteExplore the inTEST Range
Custom Build Specifications
Overview of Prodigy's custom engineering capabilities, ASME BPE fabrication standards, and available compliance configurations.
Request Data Sheet or QuoteRegulatory Guides
Schedule III Rescheduling: What Cannabis Operators Need to Know
A comprehensive guide to the April 2026 DEA final order rescheduling medical marijuana to Schedule III — what it means for operators, what compliance steps are required, and how Prodigy systems support the transition.
Request GuideFDA cGMP for Cannabinoid API Manufacturers
An overview of FDA current Good Manufacturing Practice requirements applicable to cannabinoid API manufacturing under 21 CFR Parts 210 and 211, with guidance on equipment qualification and documentation.
Request GuideICH Q7 Compliance Guide for Cannabinoid APIs
A practical guide to ICH Q7 requirements for cannabinoid API manufacturers — covering equipment design, process validation, analytical testing, and documentation requirements.
Request GuideEU GMP EudraLex Volume 4 — Equipment Requirements
Summary of EU GMP equipment requirements under EudraLex Volume 4 Annex 1 and Annex 15, with guidance on how Prodigy systems support EU market authorization.
Request GuideIQ/OQ/PQ Validation Guide for Extraction Equipment
A step-by-step guide to equipment qualification for pharmaceutical extraction systems — covering Installation Qualification, Operational Qualification, and Performance Qualification protocols.
Request GuideASME BPE-2024 — What It Means for Your Equipment
An explanation of the ASME Bioprocessing Equipment standard and why it matters for pharmaceutical equipment procurement, supplier qualification, and regulatory submissions.
Request GuideIndustry News & Updates
DEA Issues Final Order Rescheduling Marijuana to Schedule III
The U.S. Department of Justice and DEA issued the final rule placing FDA-approved drug products containing marijuana and qualifying marijuana activity conducted under a state medical-marijuana license in Schedule III of the Controlled Substances Act.
Source: DEA / DOJCannabinoid Pharmaceutical Market Valued at $15.08 Billion
The global cannabinoid pharmaceutical market reached $15.08 billion in 2025 and is projected to grow to $96.36 billion over the next decade, driven by regulatory reform and pharmaceutical market entry.
Source: Insight Ace AnalyticASME BPE-2024 Standard Released — Updated Requirements for Bioprocessing Equipment
The American Society of Mechanical Engineers released the updated BPE-2024 standard for bioprocessing equipment, incorporating new requirements for pharmaceutical-grade fabrication and documentation.
Source: ASMENeed a Specific Resource?
Contact our team for custom documentation, compliance guidance, or technical specifications for your application.
Contact Us